Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Rasmussen

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
JAMIA Open|October 20, 2023
Hypermedia-based software architecture enables Test-Driven DevelopmentAndrew R Post, Nancy Ho, Erik Rasmussen, et al.
The Science of the Total Environment|April 22, 2018
Technologies for the management of MSW incineration ashes from gas cleaning: New perspectives on recovery of secondary raw materials and circular economyMargarida J Quina, Elza Bontempi, Anna Bogush, et al.
Cytometry. Part B, Clinical Cytometry|August 12, 2009
Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosusShelley Sims Belouski, Daniel Wallace, Michael Weisman, et al.
Toxicologic Pathology|October 27, 2009
Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassayIgor Mikaelian, Denise Coluccio, Gerard M Hirkaler, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2019
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinomaChristophe Massard, Jean-Charles Soria, Jürgen Krauss, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIIIMark Rosenthal, Richard Curry, David A Reardon, et al.
Oncotarget|December 20, 2014
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumoursDavid S Hong, Razelle Kurzrock, Marilyn Mulay, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2015
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapiesBenjamin Wu, Rebeca Melara, Erik Rasmussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid TumorsAfshin Dowlati, Gordana Vlahovic, Ronald B Natale, et al.
Chiropractic & Manual Therapies|February 23, 2022
Appropriateness of referrals from primary care for lumbar MRISusanne Brogaard Krogh, Tue Secher Jensen, Nanna Rolving, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
JAMIA Open|October 20, 2023
Hypermedia-based software architecture enables Test-Driven DevelopmentAndrew R Post, Nancy Ho, Erik Rasmussen, et al.
The Science of the Total Environment|April 22, 2018
Technologies for the management of MSW incineration ashes from gas cleaning: New perspectives on recovery of secondary raw materials and circular economyMargarida J Quina, Elza Bontempi, Anna Bogush, et al.
Cytometry. Part B, Clinical Cytometry|August 12, 2009
Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosusShelley Sims Belouski, Daniel Wallace, Michael Weisman, et al.
Toxicologic Pathology|October 27, 2009
Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassayIgor Mikaelian, Denise Coluccio, Gerard M Hirkaler, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2019
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinomaChristophe Massard, Jean-Charles Soria, Jürgen Krauss, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIIIMark Rosenthal, Richard Curry, David A Reardon, et al.
Oncotarget|December 20, 2014
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumoursDavid S Hong, Razelle Kurzrock, Marilyn Mulay, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2015
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapiesBenjamin Wu, Rebeca Melara, Erik Rasmussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid TumorsAfshin Dowlati, Gordana Vlahovic, Ronald B Natale, et al.
Chiropractic & Manual Therapies|February 23, 2022
Appropriateness of referrals from primary care for lumbar MRISusanne Brogaard Krogh, Tue Secher Jensen, Nanna Rolving, et al.
Pageof 5